MATTER STATUS REPORT — Q3 2023
PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGED / ATTORNEY WORK PRODUCT
October 3, 2023
Prepared By: Calderwood & Harkness LLP
Authors: Leonard Cross, Responsible Partner, Tax Department; Sylvia Hartwell, Billing Partner, Tax Department
Matter Number: 1018-00009
Reporting Period: July 1, 2023 – September 30, 2023
TO:
Marcus Whitfield, Vice President, Global Tax, Penterra Pharmaceuticals Corp.
Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp.
Rajesh Iyer, Chief Financial Officer, Penterra Pharmaceuticals Corp.
FROM:
Leonard Cross and Sylvia Hartwell, Calderwood & Harkness LLP
RE:
Quarterly Status Report — IRS Transfer Pricing Examination Defense, Tax Years 2017–2020
This report is protected by the attorney-client privilege and the attorney work-product doctrine. It contains the confidential legal assessments, mental impressions, and litigation strategy of outside counsel. This report is prepared solely for the named recipients and should not be disclosed, disseminated, or forwarded to any third party without the prior written consent of Calderwood & Harkness LLP. Inadvertent disclosure of this report does not constitute a waiver of any applicable privilege.
Right-click to update Table of Contents
I. Executive Summary
This quarterly report covers what has become the most significant period of the IRS's transfer pricing examination of Penterra Pharmaceuticals Corp. ("PPC") to date. Most critically, the Internal Revenue Service issued its Notice of Proposed Adjustment ("NOPA") on October 12, 2023. Although the NOPA was formally issued just outside the Q3 reporting period, we address it substantively in this report given its critical importance and its proximity to the date of this report, as well as the fact that the NOPA was anticipated and substantially prepared for throughout Q3 2023.
The IRS Large Business & International Division ("LB&I"), Northeast Transfer Pricing Practice, Exam Team LB&I-NE-TP-2022-00641, has proposed total adjustments of approximately $380.4 million across Tax Years 2017 through 2020. The proposed adjustments challenge PPC's transfer pricing methodology on two principal fronts: (i) the cost-sharing arrangement ("CSA") between PPC and Penterra Biopharma International DAC ("PBI"), an Irish-resident company, and (ii) the legacy intellectual property royalty arrangement under which PBI compensates PPC for use of pre-existing intangible property. In addition to these pricing-based challenges, the IRS asserts that PBI lacked sufficient economic substance to justify its role as intellectual property owner and CSA participant—a position that, as discussed below, is contradicted by substantial evidence assembled over the course of this engagement.
A proposed penalty under Internal Revenue Code ("IRC") § 6662(e) for substantial valuation misstatement accompanies the adjustments, totaling approximately $15.98 million.
During Q3 2023, Calderwood & Harkness LLP ("C&H") completed responses to the final Information Document Requests ("IDRs") issued by the examination team (through IDR No. 47), engaged in substantive discussions with IRS economist Dr. Alan Washburne regarding his economic methodology, and participated in a call with IRS Office of Chief Counsel Attorney-Advisor Franklin Rosario regarding the legal positions underlying the anticipated NOPA. The completion of the IDR phase marks the conclusion of the information-gathering stage of the examination and the transition into the administrative dispute resolution process.
C&H's assessment remains that PPC's transfer pricing positions are well-supported, grounded in strong contemporaneous documentation prepared under IRC § 6662(e) penalty-protection standards by Crestfield & Associates LLP, and bolstered by comprehensive economic analyses prepared by Whitmore Valuation Group LLC ("WVG"). C&H is confident in the defensibility of PPC's transfer pricing methodology at IRS Appeals and, if necessary, in litigation before the United States Tax Court or the Court of Federal Claims.
The immediate next steps include a detailed analysis of the NOPA, preparation for the anticipated 30-Day Letter, development and filing of a formal Protest to IRS Appeals, and preparation of a comprehensive Appeals strategy. These tasks are described in greater detail in Sections IV and XI below.
II. Examination Status and Q3 Activity
A. IDR Completion
The Information Document Request phase of the examination is now complete. Over the course of the examination, a total of forty-seven (47) IDRs were issued by the IRS examination team between June 2022 and September 2023. During Q3 2023, C&H prepared and submitted responses to IDRs Nos. 40 through 47, the final tranche of information requests. The responses were prepared in coordination with PPC's internal tax and legal departments, as well as with WVG and Crestfield, and were submitted in accordance with all applicable deadlines or approved extensions.
The IDRs addressed in Q3 2023 are summarized as follows:
• IDR No. 40 (response dated July 18, 2023): This IDR requested Forms 5471 (Information Return of U.S. Persons with Respect to Certain Foreign Corporations) for PBI and Penterra Holdings Luxembourg S.à r.l. ("PHL") for Tax Years 2017 through 2020. C&H compiled and organized the required returns, including all applicable schedules and attachments, and submitted them along with a cover letter identifying the specific documents produced.
• IDR No. 41 (response dated July 25, 2023): This IDR sought supplemental documentation regarding PBI's governance structure, including board of directors meeting minutes, delegation of authority matrices, and organizational charts for the relevant tax years. C&H worked with PBI's Managing Director, Aidan Naughton, and PPC's corporate secretary function to compile the responsive materials.
• IDR No. 42 (response dated August 3, 2023): This IDR requested documentation of PPC's R&D cost allocation methodology under the CSA, including detailed breakdowns of intangible development costs ("Coss") by project, cost center, and category for each tax year. C&H coordinated with PPC's R&D finance team and WVG to prepare the responsive materials.
• IDR No. 43 (response dated August 10, 2023): This IDR requested documentation regarding PBI's regulatory affairs activities, including a schedule of marketing authorization applications filed with non-Americas regulatory authorities, associated regulatory expenses, and personnel involved in the regulatory submission process. Materials were compiled with the assistance of Thornbury & Keogh and PBI personnel.
• IDR No. 44 (response dated August 22, 2023): This IDR sought PBI capital expenditure records, equipment purchases, and information technology infrastructure investments for 2017 through 2020. The responsive materials included fixed asset schedules, purchase orders, and vendor contracts evidencing PBI's independent investment in its operational infrastructure.
• IDR No. 45 (response dated September 8, 2023): This IDR requested documentation regarding PBI's commercial activities, including distribution agreements, pricing analyses for key non-Americas markets, and revenue breakdowns by product and territory for TY 2017–2020.
• IDR No. 46 (response dated September 15, 2023): This IDR sought additional documentation regarding the Platform Contribution Transaction ("PCT") payment, including the original valuation analysis, board resolutions authorizing the transaction, and subsequent true-up calculations.
• IDR No. 47 (response dated September 29, 2023): This was the final IDR issued by the examination team. It requested supplemental documentation including additional employee compensation data for PBI personnel (base salary, bonus, and equity compensation) and travel records for PBI executives and key employees for the tax years under examination. The response was submitted to the IRS examination team on the final business day of Q3 2023.
All IDR responses were submitted to Lead Revenue Agent Patricia Dunleavy in accordance with agreed-upon deadlines or extensions approved through the IDR enforcement process. It is worth noting that no summons enforcement actions were initiated by the IRS at any point during the examination. While there were periodic disagreements regarding the scope and timing of certain IDRs—particularly IDR Nos. 22, 31, and 38, which involved privilege-sensitive materials—all such disputes were resolved through negotiation and the standard IDR escalation process without requiring formal enforcement proceedings.
Throughout the IDR process, C&H maintained a comprehensive privilege log for all documents withheld on grounds of attorney-client privilege and the attorney work-product doctrine. The privilege log currently encompasses 342 entries and was updated through the final IDR response. The examination team did not formally challenge any privilege assertions, although Lead Revenue Agent Dunleavy raised informal questions regarding certain entries during Q2 2023, which were resolved through supplemental privilege log descriptions.
B. Interaction with IRS Economist
A significant development during Q3 2023 was the continued engagement with Dr. Alan Washburne, the IRS Transfer Pricing Practice economist assigned to the examination. Dr. Washburne's involvement is central to the IRS's proposed adjustments, as his economic analyses form the quantitative basis for both the CSA cost-sharing ratio adjustments and the legacy IP royalty rate adjustments set forth in the NOPA.
On August 15, 2023, C&H (Leonard Cross and Garrett Simmons) participated in a meeting by videoconference with Dr. Washburne to discuss his economic methodology, comparable selection criteria, and discount rate assumptions as applied to PPC's transfer pricing arrangements. The meeting lasted approximately two hours and forty-five minutes and provided important insight into the economic foundation of the IRS's anticipated positions.
Key observations from the August 15, 2023 meeting with Dr. Washburne include the following:
• PCT Revaluation: Dr. Washburne indicated that he applied an income method (Discounted cash flow, or "DCF") to revalue the Platform Contribution Transaction. He employed a weighted average cost of capital ("WACC") of 7.2%, compared to the 9.8% WACC applied by PPC's economists at WVG in the original PCT valuation. Dr. Washburne's lower discount rate, combined with revenue projections that significantly exceeded PPC's original estimates, resulted in a substantially higher PCT valuation of approximately $852 million, compared to PPC's PCT payment of $312 million. Dr. Washburne's revenue projections appear to incorporate the benefit of hindsight—using actual realized revenues rather than the ex ante projections that were available and appropriate at the time of the PCT—a methodology that raises significant legal and economic concerns.
• CUT Comparable Selection for Royalty Rate: Dr. Washburne selected a different set of comparable uncontrolled transaction ("CUT") comparables for the legacy IP royalty rate analysis. His comparable set yielded an arm's-length royalty rate of 11.0% of net sales, compared to PPC's reported rate of 4.5%. C&H's preliminary review indicates that Dr. Washburne's CUT selection includes agreements that are not sufficiently comparable to the PPC-PBI arrangement due to differences in the intangible property transferred, the contractual terms, and the geographic scope of the licenses. Several of his selected comparables involve early-stage pharmaceutical compounds with significantly higher risk profiles than PPC's mature, revenue-generating products.
• Cost-Sharing Percentages: Dr. Washburne challenged PBI's cost-sharing percentages under the CSA, asserting that PPC's projections of reasonably anticipated benefits ("RABs") systematically understated U.S.-source value. His analysis adjusted PBI's cost-share upward by 8 to 12 percentage points across the four tax years, based on a reallocation of projected benefits that assigns a greater share of anticipated value to the Americas territory controlled by PPC. Dr. Washburne's RAB methodology does not appear to adequately account for the significant and growing revenue contribution of PBI's non-Americas markets, which represented approximately 47% of global revenues by TY 2020.
• DEMPE Functions: Dr. Washburne expressed skepticism regarding PBI's level of Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions, suggesting that key value-driving activities remained centralized in the United States under PPC's direction and control. This position is central to the IRS's economic substance challenge and is addressed further in Section VI below, where C&H summarizes the extensive evidence of PBI's substantive functional contributions.
C&H's internal assessment is that Dr. Washburne's analysis contains significant methodological weaknesses that will be highlighted in the formal Protest and at the Appeals conference. The most critical vulnerabilities in his analysis include the following:
(a) His CUT selection for the royalty rate analysis includes non-comparable agreements that should be excluded under the comparability standards of Treasury Regulations § 1.482-4(c);
(b) His discount rate assumptions for the PCT revaluation do not adequately account for the risk profile of the intangible development activities at the time of the PCT, as required under Treasury Regulations § 1.482-7;
(c) His failure to adequately account for PBI's substantive DEMPE functions and risk-bearing undermines both the cost-sharing and economic substance aspects of his analysis; and
(d) His use of actual realized revenues rather than ex ante projections in the PCT revaluation is inconsistent with the arm's-length standard and existing case law, including Tarrant Group v. Commissioner, 133 T.C. 297 (2009).
Dr. Helena Vasquez and Dr. Rohan Chakrabarti at Whitmore Valuation Group LLC are preparing a detailed rebuttal memorandum addressing each element of Dr. Washburne's economic analysis. The rebuttal memorandum is being prepared for use in the Protest filing and at the IRS Appeals conference, and will include updated comparable analyses, sensitivity analyses on WACC assumptions, and a comprehensive functional analysis demonstrating PBI's DEMPE contributions.
C. Interaction with IRS Chief Counsel
On September 20, 2023, C&H (Leonard Cross) participated in a telephone conference with IRS Office of Chief Counsel Attorney-Advisor Franklin Rosario regarding the legal positions underlying the anticipated NOPA. The call was initiated by the IRS examination team as part of its pre-NOPA coordination with Chief Counsel.
During the call, Attorney-Advisor Rosario indicated that the IRS intended to assert both IRC § 482 allocation adjustments and an economic substance challenge to PBI's participation in the CSA. Rosario explained that the legal framework for the proposed adjustments rested on the Commissioner's broad authority under IRC § 482 to allocate income among commonly controlled entities to clearly reflect income, and that the economic substance challenge would be grounded in a facts-and-circumstances analysis of PBI's role and functions. Rosario referenced Senior Counsel Donna Hirabayashi as having provided substantive support for the legal positions being developed.
C&H used the September 20 call to preview certain of PPC's defenses, including the strength of PPC's contemporaneous documentation and the extensive evidence of PBI's economic substance, without conceding any positions or making any binding representations. The purpose of this engagement was to put the IRS on notice of the substantive nature of PPC's defenses in advance of the NOPA issuance and to establish a professional working relationship with the Chief Counsel attorneys who will continue to be involved as the matter proceeds through the administrative process.
D. Examination Team Personnel
There were no changes to the IRS examination team during Q3 2023. The examination team remains composed of the following individuals:
C&H has maintained a professional and cooperative working relationship with the examination team throughout the engagement, and we anticipate continued engagement with some or all of these individuals as the matter transitions to the Appeals phase.
III. Notice of Proposed Adjustment (NOPA) — October 12, 2023
A. Issuance and Overview
As noted in the Executive Summary, although the NOPA was formally issued on October 12, 2023—technically falling outside the Q3 2023 reporting period—it is addressed substantively in this report given its critical importance to the engagement and the fact that the NOPA was anticipated and substantially prepared for during Q3 2023. The issuance of the NOPA represents the culmination of the IRS examination team's information-gathering and analytical work over the past sixteen months, and marks the formal beginning of the dispute resolution phase of the engagement.
The NOPA was issued for all four tax years under examination: Tax Years 2017, 2018, 2019, and 2020. The total net proposed adjustment across all four years is $380.4 million. The NOPA was signed by Supervisory Revenue Agent Gerald Meskill and was accompanied by a supporting economic report prepared by Dr. Washburne and a legal memorandum prepared by Attorney-Advisor Rosario.
B. Breakdown of Proposed Adjustments
The proposed adjustments are organized into three principal components, as summarized below.
1. CSA Cost-Sharing Ratio Adjustments ($235.01 Million)
The IRS proposes increasing PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points across each tax year. The IRS asserts that PPC's projections of reasonably anticipated benefits systematically understated U.S.-source value, resulting in PBI bearing an insufficient share of the intangible development costs incurred under the arrangement. The proposed adjustments are calculated as follows:
The IRS's RAB methodology increases the proportion of anticipated benefits allocated to the U.S. territory on the basis that PPC's original projections underweighted U.S. revenue growth relative to non-Americas revenue growth. As discussed in Section II.B above, C&H believes this methodology is flawed because it does not adequately account for PBI's substantial and growing contribution to non-Americas market development, including significant revenue growth in European, Asia-Pacific, and emerging markets during the examination period.
2. Legacy IP Royalty Rate Adjustments ($188.04 Million)
The IRS proposes increasing the royalty rate payable by PBI to PPC for the use of pre-existing intellectual property from PPC's reported rate of 4.5% of net sales to 11.0% of net sales. The IRS bases this adjustment on CUT data drawn from third-party pharmaceutical licensing agreements that Dr. Washburne identified as comparable to the PPC-PBI arrangement. The proposed adjustments are calculated as follows:
C&H's preliminary assessment is that the IRS's proposed 11.0% royalty rate is significantly above the arm's-length range. Whitmore Valuation Group's CUT analysis, based on fourteen comparable pharmaceutical license agreements, identified an interquartile range of 3.1% to 6.8%, with a median of 4.4%. PPC's reported royalty rate of 4.5% falls squarely within the arm's-length range and is virtually at the median of the comparable set. The IRS's proposed rate of 11.0% falls well outside this range and is driven by the inclusion of non-comparable agreements that involve different intangible property characteristics, risk profiles, and contractual terms.
3. Economic Substance Challenge
In addition to the pricing-based adjustments described above, the IRS asserts that PBI lacked sufficient economic substance to justify its role as intellectual property owner and CSA participant. The IRS's position is that key DEMPE functions remained in the United States under PPC's direction and control, and that PBI served primarily as a conduit entity without the personnel, infrastructure, or decision-making authority to justify its contractual entitlement to residual returns from non-Americas markets.
This position is integrated into the CSA and royalty adjustments rather than resulting in a separate numerical adjustment. However, the economic substance challenge has significant implications for the overall defensibility of PPC's structure, as it goes to the fundamental question of whether PBI is a bona fide economic participant in the value creation process or merely a nominal party to the intercompany arrangements.
As discussed in detail in Section VI below, C&H has assembled extensive evidence of PBI's economic substance, including documentation of 185 employees, 42 board meetings held in Dublin during the examination period, €47.2 million in cumulative regulatory expenditures across 68 country markets, and independent commercial decision-making authority exercised by PBI management. C&H is confident that the economic substance challenge will not withstand scrutiny at Appeals or in litigation.
4. Correlative Offset and Net Adjustment
The IRS allowed a correlative offset of $42.65 million to avoid double-counting between the CSA cost-sharing ratio adjustments and the legacy IP royalty rate adjustments, where both adjustments would otherwise produce overlapping income allocations for the same underlying transactions.
The net proposed adjustment is calculated as follows:
CSA Cost-Sharing Ratio Adjustments: $235.01M
Legacy IP Royalty Rate Adjustments: $188.04M
Less: Correlative Offset: ($42.65M)
Net Proposed Adjustment: $380.40M
5. Proposed Penalty
The NOPA includes a proposed penalty under IRC § 6662(e) for substantial valuation misstatement. The penalty is calculated at 20% of the underpayment of tax attributable to the proposed adjustments:
Proposed adjustment: $380.4M
Federal income tax at 21%: $79.88M
Penalty at 20% of underpayment: $15.98M (approximately)
The IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h). The reservation of the 40% penalty is notable and suggests that the IRS may seek to assert it at a later stage if negotiations do not progress favorably. However, the threshold for the gross valuation misstatement penalty—requiring a 400% or more overstatement—is significantly higher, and C&H does not believe the facts support such an assertion.
C. Tax Impact at Full Proposed Adjustment
If the proposed adjustments were sustained in full, the total financial exposure to PPC would be as follows:
Interest on the underpayment would accrue from the due date of each return through the date of payment at the applicable federal underpayment rate, which is currently the federal short-term rate plus 3 percentage points. The interest calculation is complex and depends on the timing and manner of resolution; C&H will prepare a detailed interest computation as part of the Appeals strategy analysis.
D. Initial Assessment of NOPA
C&H and Whitmore Valuation Group have conducted a preliminary review of the NOPA and its supporting economic report and legal memorandum. While a full analysis is underway (with a target completion date of October 20, 2023, as discussed in Section XI), our initial assessment is that the IRS's positions are overstated and vulnerable on multiple fronts.
The principal weaknesses in the IRS's positions are summarized as follows:
CSA Cost-Sharing Ratio Adjustments. The IRS's proposed increases to PBI's cost-sharing percentage rely on revenue projections that fail to account for PBI's substantial contribution to non-Americas market development. PBI's non-Americas revenues grew from $2.17 billion in TY 2017 to $2.41 billion in TY 2020, driven by PBI's own commercial strategy, regulatory affairs, and market access activities. The IRS's RAB methodology attributes a disproportionate share of projected benefits to the U.S. territory without adequately crediting PBI's role in generating non-Americas revenues.
Legacy IP Royalty Rate. The IRS's proposed royalty rate of 11.0% is well above the interquartile range of 3.1% to 6.8% identified in Whitmore's CUT analysis of fourteen comparable pharmaceutical license agreements, which yielded a median of 4.4%. PPC's reported royalty rate of 4.5% is within the arm's-length range and is virtually at the median. Dr. Washburne's comparable set includes agreements that are distinguishable from the PPC-PBI arrangement on the basis of intangible property type, development stage, geographic scope, and contractual terms. A rigorous comparability analysis under Treasury Regulations § 1.482-4(c) should result in the exclusion of several of Dr. Washburne's selected comparables.
Economic Substance Challenge. The IRS's assertion that PBI lacked sufficient economic substance is contradicted by extensive evidence assembled over the course of this engagement, including:
• 185 employees at PBI, up from 52 at incorporation in 2012, including regulatory affairs, medical affairs, commercial strategy, and supply-chain management personnel;
• 42 board of directors meetings held in Dublin during 2017–2020 (quarterly meetings plus special sessions);
• €47.2 million in cumulative expenditures on regulatory submissions across 68 country markets during TY 2017–2020;
• Approximately 18,000 square feet of office space at Sandyford Business Park, Dublin (4th Floor, Claremont House, Dublin D18 K7T4);
• Independent pricing decisions across 68 non-Americas country markets;
• Independent banking with Glenmore Bank Ireland plc; and
• PBI bore market risk for non-Americas territories and made key commercial decisions regarding pricing, market entry timing, and distribution partner selection.
PCT Valuation. PPC's PCT payment of $312 million falls within WVG's arm's-length range of $278 million to $361 million (computed at a WACC of 9.8%), which itself is based on reasonable, contemporaneous projections. The IRS's PCT valuation of $852 million is derived from an inappropriately low WACC of 7.2% and revenue projections that incorporate the benefit of hindsight in a manner inconsistent with the arm's-length standard and the contemporaneous valuation requirements of Treasury Regulations § 1.482-7(g)(2).
Penalty Protection. PPC's contemporaneous transfer pricing documentation was prepared by Crestfield & Associates LLP under IRC § 6662(e) penalty-protection standards. The documentation includes a comprehensive functional analysis, selection and application of the best method, identification and analysis of comparable transactions, and a detailed economic analysis supporting the arm's-length nature of PPC's intercompany pricing. This documentation provides a strong foundation for penalty abatement on reasonable-cause grounds under IRC § 6662(e)(3)(B) and Treasury Regulations § 1.6662-6.
IV. Upcoming Procedural Steps
A. 30-Day Letter
A 30-Day Letter from the IRS is anticipated imminently following the issuance of the NOPA. (We note that the 30-Day Letter was in fact issued on November 8, 2023, shortly after the date of this report, consistent with our expectations.) The 30-Day Letter will formally transmit the examination results to PPC and will provide PPC with the following options:
(a) Accept the proposed adjustments and execute an agreement form (Form 870 or Form 4549);
(b) File a formal Protest to the IRS Office of Appeals within thirty days of the date of the letter; or
(c) Take no action, in which case the IRS will proceed to issue a statutory notice of deficiency (90-Day Letter), preserving PPC's right to file a petition in the United States Tax Court.
C&H's Recommendation: C&H recommends that PPC file a formal Protest and seek resolution at IRS Appeals. The Appeals process offers PPC the best opportunity to achieve a favorable resolution of the proposed adjustments without the time, expense, and uncertainty of litigation. IRS Appeals officers have settlement authority and are instructed to consider the hazards of litigation in evaluating proposed adjustments, which creates meaningful opportunities for negotiated reductions. If Appeals does not produce an acceptable result, PPC retains its right to proceed to litigation in the Tax Court or the Court of Federal Claims.
B. Formal Protest Preparation
C&H will prepare a comprehensive formal Protest contesting all proposed adjustments set forth in the NOPA. The Protest will be a detailed legal and factual submission, structured in accordance with IRS procedures and designed to provide the Appeals officer with a thorough understanding of PPC's positions and the weaknesses of the examination team's analysis.
The Protest will include detailed statements of fact and law addressing the following:
(a) CSA Cost-Sharing Ratios: Defense of PPC's cost-sharing ratios under Treasury Regulations § 1.482-7, demonstrating that PPC's projections of reasonably anticipated benefits were reasonable, consistent with industry practice, and supported by contemporaneous documentation and economic analysis.
(b) Arm's-Length Royalty Rate: Defense of the 4.5% arm's-length royalty rate under Treasury Regulations § 1.482-4 and the CUT method, including a detailed comparability analysis demonstrating that PPC's rate falls within the interquartile range of properly selected comparable transactions.
(c) PCT Valuation: Defense of the $312 million PCT payment under the income method/DCF analysis, including a demonstration that the WACC of 9.8% applied by WVG was appropriate and that the IRS's 7.2% WACC does not reflect the risk profile of the intangible development activities at the time of the PCT.
(d) PBI Economic Substance and DEMPE Functions: Comprehensive demonstration of PBI's economic substance, including its 185-person workforce, governance structure, regulatory affairs activities, commercial operations, risk-bearing, and independent decision-making authority across 68 non-Americas markets.
(e) Penalty Protection: Defense against the proposed IRC § 6662(e) penalty based on PPC's contemporaneous transfer pricing documentation, reasonable-cause defense, and good-faith reliance on independent professional advice from Crestfield & Associates.
The Protest will be accompanied by the following exhibits:
• PPC corporate structure chart (legal entity structure and intercompany relationships)
• CSA summary and cost-sharing calculations
• WVG economic analyses, including CUT analysis, CPM/TNMM benchmarking, and PCT DCF valuation
• PBI substance evidence package (organizational charts, employee rosters, board minutes summaries, regulatory expenditure schedules, office lease documentation, banking documentation)
• Contemporaneous transfer pricing documentation prepared by Crestfield & Associates
• Penalty protection memorandum
The target filing date for the Protest is within thirty days of the 30-Day Letter, with the possibility of requesting an extension of time if additional preparation time is needed to finalize the WVG rebuttal memorandum.
C. Appeals Strategy
C&H is developing a comprehensive Appeals strategy with the goal of resolving the matter at IRS Appeals at a substantial reduction from the proposed $380.4 million in adjustments. The Appeals strategy will be informed by C&H's analysis of the NOPA, WVG's rebuttal of Dr. Washburne's economic analysis, and a detailed hazards-of-litigation assessment.
Following the filing of the Protest, C&H will prepare the following strategy documents for PPC management review and approval:
• A detailed Appeals strategy memorandum setting forth C&H's recommended approach to the Appeals conference, including identification of the strongest and weakest aspects of PPC's positions and the IRS's positions;
• A hazards-of-litigation analysis quantifying the range of potential outcomes if the matter were to proceed to litigation, taking into account the legal and factual strengths and weaknesses of each component of the proposed adjustments; and
• A settlement authority memorandum recommending a range of acceptable settlement outcomes for PPC management consideration and approval, including analysis of the financial, accounting, and business implications of various settlement scenarios.
C&H will schedule a meeting with PPC's tax, legal, and finance leadership to discuss the Appeals strategy and settlement authority prior to the Appeals conference.
V. Coordination with Third Parties
A. Whitmore Valuation Group LLC
Whitmore Valuation Group LLC ("WVG"), led by Dr. Helena Vasquez (Managing Director) and Dr. Rohan Chakrabarti (Senior Director), continues to provide critical economic analysis support in connection with the transfer pricing examination defense. WVG's engagement is structured under a Kovel arrangement (reference: Matter 1018-00009-KV, executed June 20, 2022), which extends the attorney-client privilege to WVG's communications and work product in connection with this matter.
During Q3 2023, WVG's activities included the following:
• Assisting C&H with IDR responses that required economic data, including the preparation of supplemental cost-sharing calculations and comparable transaction analyses responsive to IDR Nos. 42, 45, and 46;
• Participating in the August 15, 2023 videoconference meeting with IRS economist Dr. Alan Washburne, during which Dr. Vasquez and Dr. Chakrabarti provided technical support to C&H and took detailed notes on Dr. Washburne's methodology and assumptions; and
• Beginning work on a formal rebuttal memorandum addressing each element of Dr. Washburne's economic analysis, including his CUT selection, WACC determination, RAB methodology, and PCT revaluation.
WVG has been directed to prepare the formal rebuttal memorandum on an expedited basis for inclusion with the Protest filing and for use at the IRS Appeals conference. The rebuttal memorandum will include updated comparability analyses, sensitivity analyses on key assumptions (including WACC and revenue growth rates), and a comprehensive response to Dr. Washburne's criticisms of PBI's DEMPE functions from an economic perspective.
WVG's blended billing rate is $650 per hour. Cumulative fees billed through Q3 2023 are approximately $1.7 million. The estimated total fees through matter close, inclusive of the rebuttal memorandum and Appeals conference preparation, are projected to be approximately $2,146,800. C&H is monitoring WVG's fees closely and will advise PPC of any significant changes to the estimate.
B. Crestfield & Associates LLP
Crestfield & Associates LLP ("Crestfield") continues to serve in a dual capacity as PPC's independent auditor and as the preparer of the contemporaneous transfer pricing documentation that forms the backbone of PPC's penalty protection defense. The engagement is led by Martin Ogilvy (Engagement Partner) and Susan Lam (Transfer Pricing Partner).
Crestfield's role during Q3 2023 focused on supporting C&H's preparation of the final IDR responses. Specifically, Crestfield provided return data, workpapers, and supporting schedules in connection with the Forms 5471 requested in IDR No. 40 and the cost allocation data requested in IDR No. 42. Crestfield also provided access to its transfer pricing documentation files for the examination period, which were cross-referenced in several IDR responses.
Looking ahead, C&H will coordinate closely with Crestfield on several important matters in Q4 2023 and beyond:
• FIN 48 / ASC 740-10 Reserve Analysis: In light of the NOPA, C&H will prepare a memorandum providing updated legal conclusions regarding PPC's uncertain tax positions for use by Crestfield in evaluating PPC's FIN 48 reserve as part of the year-end 2023 financial statement audit. This coordination is critical to ensure that PPC's financial reporting accurately reflects the current status of the transfer pricing examination.
• Penalty Protection Documentation: Crestfield's contemporaneous transfer pricing documentation will be a central exhibit in the Protest filing, and C&H will coordinate with Crestfield to ensure that the documentation is properly organized and presented to support the reasonable-cause defense.
C. Thornbury & Keogh
Thornbury & Keogh ("T&K"), led by Ciarán Thornbury (Lead Partner), continues to serve as Irish tax advisors to PBI and Penterra Manufacturing Ireland Ltd. ("PMI"). T&K's role in the engagement encompasses Irish tax law analysis, coordination with Irish Revenue on matters affecting PBI, and assistance with Irish-side documentation requests arising from the IRS examination.
During Q3 2023, T&K assisted C&H with Irish-side documentation requests, including materials related to PBI's Knowledge Development box ("KDB") claims and Irish Revenue filings, which were responsive to IDR No. 30 and related follow-up requests. T&K also provided guidance on Irish transfer pricing requirements and the consistency of PBI's Irish filings with its U.S. reporting positions.
Looking ahead, T&K will be engaged on dual-jurisdiction aspects of the matter, including potential competent authority proceedings and Mutual Agreement Procedure ("MAP") considerations under Article 25 of the United States-Ireland Income Tax Treaty. If the proposed adjustments are sustained in whole or in part, a competent authority request may be appropriate to mitigate double taxation of the same income by the United States and Ireland. C&H will coordinate with T&K on the timing and strategy for any competent authority filing.
T&K's fees billed through Q3 2023 total approximately €250,000 (approximately $273,000 at the average USD/EUR exchange rate for the period).
VI. PBI Substance Evidence — Summary Update
The economic substance of PBI is a central issue in the IRS's proposed adjustments and will be a key focus of the Protest and Appeals proceedings. C&H's functional analysis of PBI, originally prepared in October 2022 and updated in March 2023, comprehensively documents PBI's operations, personnel, governance, and decision-making authority. The following is a summary of the key substance evidence assembled over the course of the engagement.
Personnel. PBI employed 185 individuals during TY 2020, up from 52 employees at the time of PBI's incorporation in 2012. PBI's workforce includes personnel in regulatory affairs, medical affairs, commercial strategy, supply-chain management, market access, pharmacovigilance, and general corporate functions. PBI's Managing Director, Aidan Naughton, has operational authority over PBI's commercial activities in non-Americas territories and reports to PBI's board of directors. During August and September 2022, C&H conducted twelve (12) key PBI employee interviews to document decision-making authority, day-to-day functional contributions, and reporting relationships. These interviews provide contemporaneous testimonial evidence of PBI's substantive role in the value chain.
Governance. PBI's board of directors held forty-two (42) meetings in Dublin during TY 2017 through TY 2020, comprising quarterly board meetings and special sessions convened to address significant business decisions including product launches, pricing strategies, distribution partner selection, and regulatory submissions. Board minutes documenting these meetings have been compiled and indexed as part of the substance evidence package.
Regulatory Affairs. PBI incurred cumulative expenditures of €47.2 million on regulatory submissions across 68 country markets during TY 2017–2020. These expenditures reflect PBI's direct and substantive involvement in obtaining and maintaining marketing authorizations in non-Americas markets, a critical DEMPE function that is performed independently by PBI personnel rather than directed or controlled by PPC.
Physical Presence. PBI maintains approximately 18,000 square feet of dedicated office space at Sandyford Business Park, Dublin (4th Floor, Claremont House, Dublin D18 K7T4). The premises house PBI's management, regulatory affairs, commercial strategy, and administrative functions.
Financial Independence. PBI maintains independent banking relationships with Glenmore Bank Ireland plc and exercises independent treasury management functions. PBI makes independent pricing decisions across 68 non-Americas country markets, taking into account local market conditions, competitive dynamics, reimbursement frameworks, and regulatory requirements.
Risk-Bearing. PBI bears market risk for non-Americas territories, including demand risk, pricing risk, regulatory risk, and foreign exchange risk. PBI makes key commercial decisions regarding product pricing, market entry timing, and distribution partner selection on an independent basis, subject to PBI board oversight.
Key Product Non-Americas Revenues (FY 2020). PBI's commercial operations generated significant revenues from its three principal products in FY 2020: Veritaxol ($1.34 billion), Imvara ($790 million), and Cerulon ($280 million). These revenue figures collectively demonstrate PBI's substantial commercial operations and its material contribution to the Penterra group's global revenue base.
Penterra Manufacturing Ireland Ltd. (PMI). PMI operates separately from PBI as a contract manufacturer under a cost-plus-8% arrangement. PMI employs 620 individuals at its manufacturing facility in Ringaskiddy, County Cork, Ireland. PMI's activities are limited to pharmaceutical manufacturing and do not include DEMPE functions; the contractual and functional separation between PBI and PMI is clearly documented.
The totality of this evidence demonstrates that PBI is a substantive business entity with genuine economic substance, performing significant DEMPE functions, bearing meaningful economic risks, and making independent commercial decisions. C&H is confident that the economic substance challenge asserted in the NOPA will not withstand scrutiny at Appeals or in litigation.
VII. Financial and Disclosure Considerations
A. FIN 48 / ASC 740-10 Reserve
PPC's current FIN 48 reserve for uncertain tax positions related to the Irish intellectual property structure stands at $62.4 million (pre-settlement basis). This reserve was established based on PPC's assessment of the probability and magnitude of potential adjustments to its transfer pricing positions, taking into account the strength of PPC's technical positions and the contemporaneous documentation supporting those positions.
In light of the NOPA, which proposes adjustments totaling $380.4 million (and a total potential cash exposure of approximately $95.86 million before interest), C&H will prepare an updated FIN 48 analysis reassessing the adequacy of PPC's reserve. The analysis will incorporate C&H's current assessment of the likelihood of sustaining PPC's positions at Appeals and, if necessary, in litigation, and will provide Crestfield with updated legal conclusions for purposes of PPC's year-end 2023 financial statement audit.
C&H will prepare a formal letter to Crestfield & Associates providing updated legal conclusions regarding the uncertain tax positions, consistent with the requirements of ASC 740-10-25 and the guidance set forth in FASB Interpretation No. 48. This letter will be delivered in advance of Crestfield's year-end 2023 audit procedures.
B. SEC Disclosure Considerations
Given PPC's status as a publicly traded company listed on the Nasdaq Stock Market (ticker: PPCA), the $380.4 million proposed adjustment raises SEC disclosure questions for PPC's upcoming Annual Report on Form 10-K for the fiscal year ending December 31, 2023. Under the SEC's disclosure framework and ASC 450 (Contingencies), PPC is required to disclose contingent liabilities that are reasonably possible of resulting in a loss, together with an estimate of the possible loss or range of loss, or a statement that such an estimate cannot be made.
C&H will prepare a memorandum analyzing PPC's disclosure obligations in connection with the NOPA, including the appropriate characterization of the transfer pricing examination and the proposed adjustments in PPC's financial statements and the Management's Discussion & Analysis section of the 10-K. The memorandum will also address the interplay between the FIN 48 reserve analysis and the SEC disclosure requirements.
C&H notes that Ridgeview Capital Management LP (Douglas Everett, Managing Partner), PPC's largest institutional shareholder at approximately 8.3% of outstanding common shares, is known to monitor ASC 740-10 disclosures and tax reserve movements closely. While this is ultimately a matter for PPC's investor relations function, C&H recommends that PPC's tax, legal, and finance leadership coordinate internally on the disclosure approach to ensure consistency between the financial statements, the 10-K disclosures, and any investor communications.
C. Hargrove Credit Facility Covenants
PPC maintains a $1.5 billion revolving credit facility with Hargrove National Bank, N.A. (Christine Bellucci, Senior Vice President, Relationship Manager). The credit agreement contains certain covenants that may be implicated by the proposed adjustments, including a tax-indemnity covenant and a material-tax-event covenant that may require notice to the lender upon the occurrence of specified tax-related events.
C&H will analyze the specific terms of the credit agreement to determine whether the $380.4 million proposed adjustment triggers any reporting obligations, consent requirements, or potential default provisions. C&H's initial view is that a proposed adjustment—as opposed to a final assessment or a court determination—should not trigger default provisions under the credit agreement, as proposed adjustments are preliminary in nature and subject to administrative and judicial review. However, the credit agreement's notice requirements and the definition of "material tax event" will need to be carefully reviewed to confirm this assessment.
Associate Leila Nazari will undertake the initial review of the credit agreement covenants and prepare a memorandum summarizing the analysis for C&H partner review and discussion with PPC's General Counsel and CFO.
VIII. Statute of Limitations
C&H continues to monitor the statute of limitations for all four tax years under examination. The current status of the assessment period for each tax year is as follows:
The issuance of the NOPA preserves the IRS's position on all four tax years, but the consent extensions for TY 2017 and TY 2018 must remain in effect through final resolution of the matter—whether through agreement at Appeals, settlement, or litigation. If the Appeals process extends beyond December 31, 2024, additional Form 872 extensions may be required for TY 2017 and TY 2018. For TY 2019 and TY 2020, extensions may become necessary depending on the timeline for resolution.
No additional extension requests are anticipated at this time, given the goal of resolving the matter through the Appeals process before December 31, 2024. C&H will continue to monitor the statute of limitations and will advise PPC promptly if additional extensions become necessary.
IX. C&H Engagement Team and Staffing
There were no changes to the C&H engagement team during Q3 2023. The current team is as follows:
C&H anticipates a significant increase in team activity during Q4 2023 and Q1 2024 as the engagement transitions from the examination phase to the Protest preparation and Appeals phase. The Protest will require substantial drafting and coordination with WVG and Crestfield, and the Appeals conference preparation will involve additional strategic analysis, witness preparation, and document organization.
C&H will assess staffing needs on an ongoing basis and will advise PPC if additional resources are required. At this time, the current four-person team is expected to be sufficient for the anticipated workload, supplemented by WVG's economic analysis team and Crestfield's tax documentation support.
X. Budget and Fee Summary
A. C&H Fees Through Q3 2023
C&H's fees billed through September 30, 2023 total approximately $3.8 million. This figure remains within the lower half of the original estimated fee range of $4.5 million to $7.0 million communicated to PPC at the commencement of the engagement.
The Protest preparation, Appeals strategy development, and Appeals conference will constitute the bulk of the remaining fee expenditure. Based on current projections, C&H estimates that total fees through matter close will fall in the range of $5.5 million to $6.2 million, which remains within the original estimated fee range.
The current billing rates for the C&H engagement team are as follows:
The 2023 billing rates were adjusted in accordance with C&H's standard annual rate increase, as communicated to PPC and reflected in the 2023 rate schedule effective January 1, 2023.
B. Whitmore Valuation Group Fees
WVG fees billed through Q3 2023 total approximately $1.7 million. Remaining work includes the preparation of the formal rebuttal memorandum addressing Dr. Washburne's economic analysis and preparation for the Appeals conference. WVG's blended billing rate is $650 per hour. Total estimated WVG fees through matter close are projected to be approximately $2,146,800.
C. Thornbury & Keogh Fees
T&K fees billed through Q3 2023 total approximately €250,000 (approximately $273,000 at the average USD/EUR exchange rate for the reporting period). Additional T&K fees may be incurred in connection with competent authority/MAP considerations and Irish Revenue coordination.
XI. Next Steps and Action Items
The following action items have been identified for the coming quarter and will be executed as described: